Patent: 8,790,656
Summary for Patent: 8,790,656
| Title: | PRRSV vaccines |
| Abstract: | The invention relates to the field of PRRS viruses and infectious clones obtained from PRRS viruses. Furthermore, the invention relates to vaccines and diagnostic assays obtainable by using and modifying such infectious clones of PRRS viruses. The invention provides a porcine reproductive and respiratory syndrome virus (PRRSV) replicon having at least some of its original PRRSV nucleic acid deleted, said replicon capable of in vivo RNA replication, said replicon further having been deprived of at least some of its original PRRSV nucleic acid and/or having been supplemented with nucleic acid derived from a heterologous microorganism. |
| Inventor(s): | Johanna Jacoba Maria Meulenberg, Monique Helene Verheije |
| Assignee: | Boehringer Ingelheim Vetmedica GmbH |
| Application Number: | US11/422,970 |
| Patent Claims: | see list of patent claims |
Details for Patent 8,790,656
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Recordati Rare Diseases, Inc. | SYLVANT | siltuximab | For Injection | 125496 | April 23, 2014 | ⤷ Start Trial | 2026-06-08 |
| Eusa Pharma (uk) Limited | SYLVANT | siltuximab | For Injection | 125496 | April 23, 2014 | ⤷ Start Trial | 2026-06-08 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 8,790,656
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Austria | E366314 | ⤷ Start Trial |
| Australia | 3198200 | ⤷ Start Trial |
| Australia | 5882898 | ⤷ Start Trial |
| Australia | 719991 | ⤷ Start Trial |
| Brazil | 9712592 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
